Table 2.

Congener-specific analysis of P31 brains.

	PCB (ng/g wet weight)			PCB (ng/g lipid)
A1254 (mg/kg/day)	0	1	6	0	1	6
Mono-orthoa
PCB70	BDL	0.5 ± 0.2	0.6 ± 0.2	BDL	8.8 ± 2.9	11 ± 4
PCB74	BDL	2.0 ± 0.9	2.8 ± 1.3	BDL	36 ± 16	50 ± 24
PCB118	BDL	29 ± 6.1	78 ± 28 **, #	BDL	537 ± 103	1,398 ± 517*, #
PCB105	BDL	11 ± 3.0	23 ± 11*	BDL	199 ± 52	408 ± 208
PCB156	BDL	4.3 ± 1.1*	18 ± 2.0**, #	BDL	80 ± 22*	329 ± 41**, #
PCB189	BDL	BDL	0.8 ± 0.3*	BDL	BDL	14 ± 5*
Di-orthoa
PCB99	BDL	22 ± 3.0*	83 ± 10**, #	BDL	398 ± 44*	1,479 ± 200**, #
PCB138	BDL	30 ± 1.1*	133 ± 18**, #	BDL	553 ± 18	2,369 ± 357**, #
PCB153	BDL	22 ± 0.7	110 ± 17**, #	BDL	412 ± 15	1,964 ± 336**, #
PCB128	BDL	5.3 ± 0.8*	10 ± 2.7**, #	BDL	97 ± 13*	171 ± 49**, #
PCB180	BDL	3.4 ± 0.3*	15 ± 2.0**, #	BDL	62 ± 5	275 ± 39**, #
PCB170	BDL	2.8 ± 0.2	13 ± 2.0**, #	BDL	52 ± 4	230 ± 40**, #
PCB158	1.1b	3.9 ± 0.2*	14 ± 2.0**, #	23.7b	72 ± 5	256 ± 39**, #
PCB166	BDL	BDL	1.3 ± 0.2**, #	BDL	BDL	22 ± 3**, #
Tri-ortho
PCB187	1.0b	1.9 ± 0.3*	6.2 ± 0.7**, #	22.6b	35 ± 5	111 ± 14**, #
PCB183	BDL	1.0 ± 0.1*	3.7 ± 0.4**, #	BDL	19 ± 3*	66 ± 8**, #

BDL, below the detection limit.

^aPCB congeners below detection limit in all samples: mono-ortho-substituted congeners 8, 28, 60, 66, and 114; di-ortho-substituted congeners 44, 49, 52, 82, 87, and 101; non-ortho-substituted congeners 37, 77, 126, and 169. Mean ± SEM (n = 4 per group).

^bConcentration detected in one of four samples.

^*p < 0.05 relative to control

^**p < 0.01 relative to control

^#p < 0.05 relative to 1 mg/kg/day A1254.